Phase 3 IGIV, 10% in Alzheimer´s Disease

This study has been terminated.
(The study was terminated because the first Phase 3 did not demonstrate efficacy on the co-primary endpoints. The known safety profile remained unchanged.)
Information provided by (Responsible Party):
Baxter Healthcare Corporation Identifier:
First received: January 20, 2012
Last updated: May 19, 2013
Last verified: May 2013
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: March 2015
  Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)